Free Trial

Verrica Pharmaceuticals Q4 2024 Earnings Report

Verrica Pharmaceuticals logo
$0.44 +0.02 (+4.23%)
As of 04:00 PM Eastern

Verrica Pharmaceuticals EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Verrica Pharmaceuticals Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
$1.30 million
Beat/Miss
Missed by -$958.00 thousand
YoY Revenue Growth
N/A

Verrica Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Verrica Pharmaceuticals Earnings Headlines

“Amazon Coin” set to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
See More Verrica Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verrica Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verrica Pharmaceuticals and other key companies, straight to your email.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals (NASDAQ:VRCA), a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

View Verrica Pharmaceuticals Profile

More Earnings Resources from MarketBeat